Health
Moderna Receives Additional $472 Million to Develop Coronavirus Vaccine – The Motley Fool
Moderna’s contract with the government has been amended to include extra funding for a 30,000-patient phase 3 study.
Moderna’s (NASDAQ:MRNA) lucrative relationship with the U.S. government took another big step forward on Sunday. The Biomedical Advanced Research and Development Authority (BARDA) amended its contract with the clinical-stage biotechnology company for an additional commitment of up to $472 million.
In April, BARDA agreed to a commitment of up to $483 million to support the advancement of Moderna’s coronavirus vaccine candidate, mRNA-1273, from phase 1 trials through FDA licensure. The total valu…
Continue Reading